Kawai Shinichi, Takagi Kenji, Kusunoki Yoshie, Nishio Shinichiro, Matsumoto Nahoko
Division of Rheumatology, Department of Internal Medicine (Omori), Toho University School of Medicine.
Nihon Rinsho. 2008 Jan;66(1):130-6.
Since Hench successfully treated a patient with rheumatoid arthritis (RA) with glucocorticoid (GC) in 1948, the clinical usefulness of GC in the management of systemic autoimmune diseases has been established. However, serious adverse reactions of GC are the severe clinical problems. In addition, some of clinical evidences of GC therapy for these diseases are still controversial due to the difficulties for conducting clinical trials. In this review, we summarize the significance of GC therapy in autoimmune diseases such as RA and systemic lupus erythematosus, based upon the clinical reports for these diseases.
自1948年亨奇用糖皮质激素（GC）成功治疗一名类风湿关节炎（RA）患者以来，GC在系统性自身免疫性疾病治疗中的临床效用已得到确立。然而，GC的严重不良反应是严峻的临床问题。此外，由于开展临床试验存在困难，GC治疗这些疾病的一些临床证据仍存在争议。在本综述中，我们基于这些疾病的临床报告，总结了GC治疗在RA和系统性红斑狼疮等自身免疫性疾病中的意义。
